Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4+ and CD8+ T cell responses lasting more than seven years

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 8, 2012, Pages 566-572

  Lind, Andreas ^a,b   Sommerfelt, Maja ^c   Holmberg, Jens Olof ^c   Baksaas, Ingebjørg ^d   Sørensen, Birger ^c   Kvale, Dag ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Bionor Pharma ASA   (Norway)

^d Mericon AS   (Norway)

Author keywords

CD107a; HIV; T cell memory; T cells; Vaccine

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; LOW DRUG DOSE; MALE;

AIDS VACCINES; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; PEPTIDES;

EID: 84864040315     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.653581     Document Type: Article

References (16)

1. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010;464:224-31.
2. Kran AM, S ør ensen B, Nyhus J, Sommerfelt MA, Baksaas I, Bruun JN, Kvale D. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004;18:1875-83.
3. Åsjö B, Stavang H, Sørensen B, Baksaas I, Nyhus J, Langeland N. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res Hum Retroviruses 2002;18: 1357-65.
4. Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, et al. Relative dominance of Gag p24-specific cytotoxic T-lymphocytes is associated with human immunodeficiency virus control. J Virol 2006;80:3122-5.
5. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborn I, Modley E, et al. CD8+ T-cells response to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53.
6. Pettersen FO, Tasken K, Kvale D. Combined Env- and Gagspecifi c T cell responses in relation to PD-1 and CD4+ T cell loss rates in HIV-1 infection. Clin Exp Immunol 2010;161:315-23.
7. Sommerfelt MA, Nyhus J, Sørensen B. Novel peptide-based HIV-1 immunotherapy. Expert Opin Biol Ther 2004;4: 349-61.
8. Kvale D, Kran AM, Sommerfelt MA, Nyhus J, Baksaas I, Bruun JN, Kvale D. Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia. AIDS 2005;19:563-7.
9. Kran AM, Sommerfelt MA, Sør ensen B, Nyhus J, Baksaas I, Bruun JN, Kvale D. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005;23:4011-5.
10. Kran AM, Sørensen B, Sommerfelt MA, Nyhus J, Baksaas I, Kvale D. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS 2006;20:627-30.
11. Kran AM, Jonassen TØ , Sommerfelt MA, Løvgården G, S ørensen B, Kvale D. Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides. AIDS 2010;24:2609-18.
12. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
13. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in non-progressors. Nat Immunol 2002;3: 1061-8.
14. Day CL, Kiepela P, Leslie AJ, van der Stok M, Nair K, Ismail N, et al. Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodefi ciency virus type 1 infection. J Virol 2007;81: 434-8.
15. Calarota SA, Foli A, Maserati R, Baldantini F, Paulucci S, Young MA, et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 2008; 180:5907-15.
16. Boström AC, Hejdeman B, Matsuda R, Fredriksson M, Fredriksson AL, Bratt G, et al. Long-term persistence of vaccination and HAART to human immunodefi ciency virus (HIV). Vaccine 2004:22; 1683-91.